Intercept Pharma (ICPT) Announces Presentation of Significant Data from OCA FLINT Trial in NASH
Tweet Send to a Friend
Intercept Pharma (NASDAQ: ICPT) announced new results from the first non-invasive evaluation of liver fibrosis in patients from the FLINT ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
